




PHARMACEUTICAL 2020

Dicerna Pharmaceuticals Inc
Rank 225 of 358





PHARMACEUTICAL 2020

Dicerna Pharmaceuticals Inc Rank 225 of 358

The relative strengths and weaknesses of Dicerna Pharmaceuticals Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Dicerna Pharmaceuticals Inc compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 66% points. The greatest weakness of Dicerna Pharmaceuticals Inc is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 64% points.

The company's Economic Capital Ratio, given in the ranking table, is 27%, being 9.2% points below the market average of 36%.

Input Variable	Value in 1000 USD
Assets, Current	556,169
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	241,735
Liabilities, Non-Current	203,479
Other Assets	34,164
Other Compr. Net Income	0
Other Expenses	39
Other Liabilities	0
Other Net Income	7,727
Other Revenues	23,904
Property and Equipment	7,076
Research and Development	109,300
Selling, General and Administrative Expense	42,751

Output Variable	Value in 1000 USD
Assets	597,409
Liabilities	445,214
Expenses	152,090
Revenues	23,904
Stockholders Equity	152,195
Net Income	-120,459
Comprehensive Net Income	-120,459
Economic Capital Ratio	27%